作者: Peter Fickert , Marion J Pollheimer , Ulrich Beuers , Carolin Lackner , Gideon Hirschfield
DOI: 10.1016/J.JHEP.2014.02.006
关键词: Primary sclerosing cholangitis 、 Gastroenterology 、 Position paper 、 Ulcerative colitis 、 Biliary fibrosis 、 Liver transplantation 、 Inflammatory bowel disease 、 Intensive care medicine 、 Medicine 、 Cholestasis 、 Anti-neutrophil cytoplasmic antibody 、 Internal medicine 、 Hepatology
摘要: Primary sclerosing cholangitis (PSC) is a chronic cholangiopathy characterized by biliary fibrosis, development of cholestasis and end stage liver disease, high risk malignancy, frequent need for transplantation. The poor understanding its pathogenesis also reflected in the lack effective medical treatment. Well-characterized animal models are utterly needed to develop novel pathogenetic concepts study new treatment strategies. Currently there no consensus on how evaluate characterize potential PSC models, which makes direct comparison experimental results exchange material between research groups difficult. International Sclerosing Cholangitis Study Group (IPSCSG) has therefore summarized these key issues position paper proposing standard requirements PSC.